USFDA21 Aug 2025, 05:53 pm
Hikal Ltd Receives US FDA Warning Letter for Jigani Facility
AI Summary
Hikal Ltd has received a warning letter from the US FDA for their Jigani, Bengaluru facility. This follows a US FDA inspection from February 3-7, 2025. The company is committed to working closely with the US FDA to resolve the issues at the earliest and upholds quality and compliance issues with utmost importance.
Key Highlights
- Hikal Ltd receives warning letter from US FDA for Jigani, Bengaluru facility
- US FDA inspection conducted from February 3-7, 2025
- Company committed to resolving issues with US FDA
- Quality and compliance issues are of utmost importance to Hikal Ltd
- Hikal Ltd aims to be compliant with cGMP quality standards across all manufacturing facilities